Cyber Monday saleUp to 70% OFF
JUBILANT PHARMOVA LTDJUBILANT PHARMOVA LTDJUBILANT PHARMOVA LTD

JUBILANT PHARMOVA LTD

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

JUBLPHARMA chart


Full chart

JUBLPHARMA upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪196.53 B‬ INR
Dividend yield (indicated)
0.42%
Price to earnings Ratio (TTM)
33.10
Basic EPS (TTM)
37.45 INR
Net income (FY)
‪771.00 M‬ INR
Revenue (FY)
‪66.96 B‬ INR
Shares float
‪65.50 M‬
Beta (1Y)
1.48

Employees


Employees (FY)
‪5.75 K‬
Change (1Y)
+746 +14.91%
Revenue / Employee (1Y)
‪139.61 K‬ INR
Net income / Employee (1Y)
‪1.61 K‬ INR

About JUBILANT PHARMOVA LTD


Sector
Health Technology
Headquarters
Noida
Founded
1978
Website
jubilantpharmova.com
ISIN
INE700A01033
FIGI
BBG000D1Q1V7
Jubilant Pharmova Ltd. engages in the provision of basic organic chemicals. It operates through the following segments: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation, Generics, and Proprietary Novel Drugs. The Radiopharma segment is involved in products for diagnosis and treatment of various diseases, including Pulmonary Embolism, Cancer, Coronary Artery Diseaseand many others. The Allergy Immunotherapy segment provides diagnostic devices for skin testing. The CDMO Sterile Injectables segment offer manufacturing services including sterile fill and finish injectables, full-service ophthalmic offer, and ampoules. The Generics segment includes development, manufacturing, distribution, sales and marketing of generics formulations. The CRDMO segment relates to drug discovery and development services. The company was founded on June 21, 1978 and is headquartered in Noida, India.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

JUBLPHARMA news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of JUBLPHARMA is 1,226.65 INR — it has decreased by −2.59% in the past 24 hours. Watch JUBILANT PHARMOVA LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange JUBILANT PHARMOVA LTD stocks are traded under the ticker JUBLPHARMA.
JUBLPHARMA stock has risen by 5.05% compared to the previous week, the month change is a −2.65% fall, over the last year JUBILANT PHARMOVA LTD has showed a 163.85% increase.
We've gathered analysts' opinions on JUBILANT PHARMOVA LTD future price: according to them, JUBLPHARMA price has a max estimate of 1,450.00 INR and a min estimate of 1,212.00 INR. Watch JUBLPHARMA chart and read a more detailed JUBILANT PHARMOVA LTD stock forecast: see what analysts think of JUBILANT PHARMOVA LTD and suggest that you do with its stocks.
JUBLPHARMA reached its all-time high on Nov 7, 2024 with the price of 1,309.90 INR, and its all-time low was 51.55 INR and was reached on Sep 30, 2003. View more price dynamics on JUBLPHARMA chart.
See other stocks reaching their highest and lowest prices.
JUBLPHARMA stock is 3.30% volatile and has beta coefficient of 1.48. Track JUBILANT PHARMOVA LTD stock price on the chart and check out the list of the most volatile stocks — is JUBILANT PHARMOVA LTD there?
Today JUBILANT PHARMOVA LTD has the market capitalization of ‪191.67 B‬, it has decreased by −1.24% over the last week.
Yes, you can track JUBILANT PHARMOVA LTD financials in yearly and quarterly reports right on TradingView.
JUBILANT PHARMOVA LTD is going to release the next earnings report on Jan 31, 2025. Keep track of upcoming events with our Earnings Calendar.
JUBLPHARMA net income for the last quarter is ‪1.03 B‬ INR, while the quarter before that showed ‪4.82 B‬ INR of net income which accounts for −78.68% change. Track more JUBILANT PHARMOVA LTD financial stats to get the full picture.
Yes, JUBLPHARMA dividends are paid annually. The last dividend per share was 5.00 INR. As of today, Dividend Yield (TTM)% is 0.42%. Tracking JUBILANT PHARMOVA LTD dividends might help you take more informed decisions.
As of Dec 3, 2024, the company has ‪5.75 K‬ employees. See our rating of the largest employees — is JUBILANT PHARMOVA LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. JUBILANT PHARMOVA LTD EBITDA is ‪9.11 B‬ INR, and current EBITDA margin is 13.38%. See more stats in JUBILANT PHARMOVA LTD financial statements.
Like other stocks, JUBLPHARMA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade JUBILANT PHARMOVA LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So JUBILANT PHARMOVA LTD technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating JUBILANT PHARMOVA LTD stock shows the buy signal. See more of JUBILANT PHARMOVA LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.